Ultimovacs (ULTI.OL) Stock Analysis & AI Equity Report
Ultimovacs (ULTI.OL) overview
Ultimovacs (ULTI.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Ultimovacs reported revenue of NOK 0m and operating profit of NOK 0m; the year-end share price was 2.33 NOK and market capitalisation was N/A. Ultimovacs is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ultimovacs's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Ultimovacs
Ultimovacs ASA is a Norwegian biotechnology company that originally developed cancer immunotherapies, including the UV1 therapeutic vaccine platform. In March 2025 it completed a business combination with Zelluna Immunotherapy AS and changed its name to Zelluna ASA, shifting the group toward off-the-shelf TCR-NK cell therapies for solid tumours and related oncology development activities.
Generate the Ultimovacs report
Ultimovacs is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ultimovacs and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.